- Trial phase
- Preclinical
- Time to market
- Unknown, earliest Phase 1 initiation expected year-end 2026; even if successful, Phase 2/3 and approval would take many years
- Why 4/10
- CUE-401 is still preclinical (IND not yet filed). The next catalyst is IND submission targeted for H2 2026, with Phase 1 initiation expected by year-end 2026, a soft timeline, not a hard dated binary. As a preclinical asset, no PDUFA or pivotal readout exists to drive a large binary move in the next ~12 months.
CUE-401 is the company's lead autoimmune candidate but remains preclinical. The stock has significant non-CUE-401 catalysts: a Phase 2 data readout for CUE-221 (anti-IgE) expected H2 2026, plus recent $50M and $30M financings that extend runway. Watch for the IND filing timeline, any delay beyond H2 2026 would be a negative signal.
Price Chart
Executive Summary
CUE-401 is Cue Biopharma's lead preclinical autoimmune asset, a first-in-class bispecific fusion protein combining modified TGF-β and IL-2 to expand regulatory T cells (Tregs). It has received positive FDA Pre-IND feedback and preclinical data shows good tolerability. IND submission is targeted for H2 2026 with Phase 1 by year-end. While the science is differentiated, CUE-401 is years from commercialization, the company has a going-concern history (partially addressed by recent $50M and $30M financings), and the stock has multiple catalysts beyond CUE-401 including a Phase 2 readout for CUE-221 (anti-IgE) in H2 2026.
How It Works
CUE-401 is a single injected protein that combines two signaling molecules, TGF-β and IL-2, both modified for safety. Together, they work to turn down the immune system by expanding "regulatory T cells" (Tregs), which act like the body's natural peacekeepers. The goal is to re-establish immune tolerance in autoimmune diseases (where the immune system mistakenly attacks the body) without broadly suppressing the entire immune system.
Trial Status
CUE-401 is in preclinical development. Cue Biopharma received positive Pre-IND feedback from the FDA in June 2025 and presented preclinical safety/tolerability data in February 2026 showing no adverse events in two non-GLP animal studies. IND submission is targeted for H2 2026, with a first-in-human Phase 1 study expected to begin by year-end 2026.
The Two-Sided Case
Upcoming Catalysts
- IND submission for CUE-401 (expected H2 2026)
- Phase 1 first-in-human study initiation (expected by year-end 2026)
- CUE-221 Phase 2 data readout in chronic spontaneous urticaria (H2 2026), a separate pipeline catalyst
- Potential partnership or option exercise by Ono Pharmaceutical for CUE-401
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Cue Biopharma, Inc. Press Release CUE ·Originating report